Showing results (31-40 of 88) with videos related to

Sort By:
Pageof 9
Journal of Affective Disorders|October 19, 2016
Long-term safety and tolerability of asenapine: A double-blind, uncontrolled, long-term extension trial in adults with an acute manic or mixed episode associated with bipolar I disorderTerence A Ketter, Suresh Durgam, Ronald Landbloom, et al.
The Journal of Clinical Psychiatry|December 4, 2014
Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trialHarry A Croft, Nunzio Pomara, Carl Gommoll, et al.
The Primary Care Companion for CNS Disorders|August 4, 2016
Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With VilazodoneArif Khan, Suresh Durgam, Xiongwen Tang, et al.
Patient Preference and Adherence|August 6, 2020
Patients' Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference QuestionnaireClifton Blackwood, Panna Sanga, Isaac Nuamah, et al.
Neuropsychiatric Disease and Treatment|May 8, 2018
Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL studyHuafang Li, Yan Li, Yu Feng, et al.
Neuropsychiatric Disease and Treatment|August 18, 2017
Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension studySuresh Durgam, Ronald P Landbloom, Mary Mackle, et al.
Innovations in Clinical Neuroscience|June 18, 2020
Innovative Approaches for Slowing Disease Progression in Parkinson's Disease: Takeaways from the 14th Annual International Society for Central Nervous System Clinical Trials and Methodology Scientific MeetingMonica Javidnia, Mark Frasier, Ira Shoulson, et al.
International Clinical Psychopharmacology|August 21, 2015
Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose studyCarl Gommoll, Giovanna Forero, Maju Mathews, et al.
Neuropsychiatric Disease and Treatment|December 31, 2020
Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable SchizophreniaMartin Lambert, Pedro Sanchez, Paul Bergmans, et al.
Clinical Drug Investigation|June 9, 2018
Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup AnalysisMaju Mathews, Huiling Pei, Adam Savitz, et al.
Pageof 9